TMS in Anxiety-Parkinson's Disease
At a glance
Conditions
NCT06999330
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
HealthPartners Neuroscience Center
Saint Paul, Minnesotano site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Bhavani Kashyap, MBBS, PhD · PRINCIPAL_INVESTIGATOR · HealthPartners Institute
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Recruitment Ratescreening
Percentage of participant who enroll and consent based on those contacted. A higher percentage indicates higher feasibility.
- Participation Rate3 weeks
Percentage of participant who start treatment after enrollment. A higher percentage indicates higher feasibility.
- Fidelity2 weeks
Percentage of participant who complete all treatment sessions. A higher percentage indicates higher fidelity.
- Completion Rate2 weeks
Percentage of participant who complete 7 of the 9 treatment visits. A higher percentage indicates higher completion.
- Adverse Events Rate - Safetyup to 12 weeks
Percentage of participant with adverse events. A lower percentage indicates a safer treatment.
- Adverse Events Safetyup to 12 weeks
Frequency of each adverse event. A higher frequency indicates a less safe treatment.